Carregant...
Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist
The optimal treatment strategy for Parkinson's disease has been debated for decades. The introduction of levodopa (LD) treatment is frequently delayed because of theoretical concerns about its toxicity or the risk of drug-induced motor complications. These concerns have resulted in “LD phobia”...
Guardat en:
| Publicat a: | Curr Neuropharmacol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Bentham Science Publishers
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4876591/ https://ncbi.nlm.nih.gov/pubmed/26644151 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2174/1570159X14666151208114634 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|